Path ID: DB00579_MESH_D009765_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D008454 | Mazindol | Drug |
| UniProt:P23975 | Sodium-dependent noradrenaline transporter | Protein |
| GO:0051620 | Norepinephrine uptake | BiologicalProcess |
| UniProt:Q01959 | Sodium-dependent dopamine transporter | Protein |
| GO:0090494 | Dopamine uptake | BiologicalProcess |
| UniProt:Q01959 | Sodium-dependent dopamine transporter | Protein |
| UniProt:P31645 | Sodium-dependent serotonin transporter | Protein |
| GO:0051610 | Serotonin uptake | BiologicalProcess |
| MESH:D009638 | Norepinephrine | ChemicalSubstance |
| MESH:D012701 | Serotonin | ChemicalSubstance |
| MESH:D004298 | Dopamine | ChemicalSubstance |
| GO:0061527 | Dopamine secretion, neurotransmission | BiologicalProcess |
| GO:0061533 | Norepinephrine secretion, neurotransmission | BiologicalProcess |
| GO:0060096 | Serotonin secretion, neurotransmission | BiologicalProcess |
| HP:0002591 | Polyphagia | PhenotypicFeature |
| MESH:D009765 | Obesity | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Mazindol | DECREASES ACTIVITY OF | Sodium-Dependent Noradrenaline Transporter |
| Mazindol | DECREASES ACTIVITY OF | Sodium-Dependent Dopamine Transporter |
| Mazindol | DECREASES ACTIVITY OF | Sodium-Dependent Serotonin Transporter |
| Sodium-Dependent Noradrenaline Transporter | POSITIVELY REGULATES | Norepinephrine Uptake |
| Sodium-Dependent Dopamine Transporter | POSITIVELY REGULATES | Dopamine Uptake |
| Sodium-Dependent Serotonin Transporter | POSITIVELY REGULATES | Serotonin Uptake |
| Norepinephrine Uptake | DECREASES ABUNDANCE OF | Norepinephrine |
| Norepinephrine | POSITIVELY CORRELATED WITH | Norepinephrine Secretion, Neurotransmission |
| Serotonin Uptake | DECREASES ABUNDANCE OF | Serotonin |
| Dopamine Uptake | DECREASES ABUNDANCE OF | Dopamine |
| Serotonin | POSITIVELY CORRELATED WITH | Serotonin Secretion, Neurotransmission |
| Dopamine | POSITIVELY CORRELATED WITH | Dopamine Secretion, Neurotransmission |
| Norepinephrine Secretion, Neurotransmission | NEGATIVELY REGULATES | Polyphagia |
| Dopamine Secretion, Neurotransmission | NEGATIVELY REGULATES | Polyphagia |
| Serotonin Secretion, Neurotransmission | NEGATIVELY REGULATES | Polyphagia |
| Polyphagia | CAUSES | Obesity |
Comment: Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.
Reference: